Trial reportBMC urology2025
Reverse placement of a double J ureteral stent improves lower urinary tract symptoms.
Trial report in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- From biofilms to fibrosis: recent advances in research on the pathological microenvironment linked to ureteral stents and their surface functionalization.Frontiers in bioengineering and biotechnology · 2026Review
- Comparison of external drainage ureteral tube versus double-J catheter placement on subjective comfort and adverse events after percutaneous nephrolithotomy.American journal of translational research · 2026Article
- Correction: Reverse placement of a double J ureteral stent improves lower urinary tract symptoms.BMC urology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the clinical efficacy and patient-reported discomfort associated with traditional versus reverse placement of double-J ureteral stents (DJUS) in patients undergoing ureteroscopic stone removal. MATERIALS AND
methodsThis prospective, randomized, single-center, one blinded, controlled study. In the control group, the double-J stent was placed with its upper end facing laterally (towards the kidney) and its lower end facing medially (towards the bladder trigone), while in the study group, the reverse was done in a mirror manner. Patients in the study group were further subdivided based on the orientation of the upper and lower tips of the stent (B1: upper medial/lower lateral, B2: both medial, B3: both lateral). Patient discomfort was assessed using the Turkish version of the Ureteral Stent Symptom Questionnaire (T-USSQ), and secondary outcomes included postprocedural hydronephrosis, hematuria, and urinary tract infection.
resultsA total of 120 patients were included and 60 patients to each the control and study groups. Forty patients were included in group B1, 8 in B2 and 12 in B3. The reverse placement group (Group B) reported significantly lower USSQ (p < 0.05) and reduced analgesic use compared to the control group. Midline crossing of the stent was significantly less frequent in the study group (11.7% vs. 30%; p = 0.013). Subgroup analysis revealed that the B1 and B3 groups had significantly lower analgesic usage and symptom scores compared to the control group, while the B2 group reported higher hydronephrosis and symptom scores.
conclusionReverse placement of DJUS, particularly when both stent ends are laterally positioned, may reduce stent-related discomfort. There is a need for a new stent design with both ends facing laterally, tentatively named "ipsi-DJUS".
trial registrationTurning the tip of the stent upside down may ease urinary symptoms" is now listed on the ISRCTN registry with study registration number ISRCTN17937257 (Date of registration: 22/10/2024). Retrospectively registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.